Emgality is a calcitonin gene-related peptide (CGRP) binding antibody studied in migraine and episodic cluster headache1
Emgality is a humanized monoclonal antibody that binds to CGRP and blocks its binding to the receptor1
There are no relevant data on the pharmacodynamic effects of galcanezumab-gnlm.1
SELECT IMPORTANT SAFETY INFORMATION
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.
Emgality works differently than many other preventive medications because it was specifically developed to bind to CGRP, a substance in the brain that may play a key role in migraine1-3
View real-world refill rate equivalent data for select preventive migraine medications